WuXi PharmaTech expands in US with acquisition of XenoBiotic Laboratories
Acquisition bolsters WuXi's Laboratory Testing Division (LTD) in bioanalytical and DMPK/ADME services, particularly in studies of radio-labelled compounds
Chinese pharmaceutical company WuXi PharmaTech, has expanded its laboratory testing division in the US with the acquisition of contract research organisation XenoBiotic Laboratories (XBL).
XBL provides bioanalytical, drug metabolism and pharmacokinetic services to the pharmaceutical, animal health, and agrochemical industries. The company employs 150 people and operates a 45,000ft2 research centre in Plainsboro, New Jersey, and a 36,000ft2 facility in Nanjing, China.
The company is FDA- and USDA-registered, New Jersey-licensed for work with radioisotopes, USDEA-licensed for conducting research with Schedule 1-5 controlled substances, and AAALAC-accredited.
Financial terms were not disclosed.
The acquisition bolsters WuXi's Laboratory Testing Division (LTD) in bioanalytical and DMPK/ADME services, particularly in studies of radio-labelled compounds.
The company said the deal expands LTD's presence in North America, provides greater flexibility in service and support options for its North American customers, and presents the opportunity for further expansion.
Jinn Wu, President and Chief Executive of XBL has been appointed Vice President and Chief Scientific Officer of LTD.
'We are very pleased to have XBL join the WuXi team,' said Ge Li, Chairman and Chief Executive of WuXi.
'Dr Wu has spent the past 27 years building a solid organisation and reputation within the industry. This business combination is an important step in WuXi's development of a comprehensive, integrated platform of R&D services to help our customers discover and develop drugs more efficiently and cost-effectively.'